Cue Biopharma Inc Net Income per Employee (CUE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Cue Biopharma Inc   (NASDAQ: CUE)
 

Cue Biopharma Inc Net Income per Employee

CUE's Quarterly Results, Trends, Rankings, Statistics
Cue Biopharma Inc recorded a cumulative net loss of $-164 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 168 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3590, from total ranking in previous quarter at 4443.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CUE Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -5,658,897 -673,207 -917,310 -1,299,414 -1,341,207
CUE's Total Ranking # 3590 # 4443 # 4039 # 4115 # 4165
Seq. Net Income Change - - - - -

CUE Company Profile >> Back to CUE Efficiency Comparisons >> Compare CUE Net Income per Employee to its Competitors

CUE Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 169
Healthcare Sector # 504
Overall Market # 3590

Net Income per Employee Statistics
High Average Low
$ -259,414 $ -1,579,075 $ -5,658,897
(Mar 31 2018)   (Jun 30 2026)




  News about Cue Biopharma Inc Income per employee

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory d...

Pioneering Partnership: Boehringer Ingelheim Teams Up with Cue Biopharma to Revolutionize Autoimmune Disease TreatmentsIn an inspiring display of innovative collaboration, two biopharmaceutical powerhouses, Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE), have announced a strategic alliance aimed at transforming the landscape of treatment options for autoimmune and inflammatory diseases. This partnership, formalized on April 14, 2025, seeks to leverage Cue Biopharma’s groundbreaking CUE501 product candidate, which represents a novel approach to B cell depletion therapy.Boehringer Ingelheim, a global leader in healthcare, has long been at the forefront of scientific research, focusing on creating breakthrough therapies that address unmet medical needs. The partnership with the Boston-based Cue Biopharma signifies an exciting step forward in their mission to develop cutting-edge solutions for patients suffering from complex autoimmune disorders.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-08T17:18:51+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.